EtanerceptWorsening of interstitial lung disease: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1732卷 / 1期

关键词：

D O I：

10.1007/s40278-018-55625-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：169 / 169

相关论文

共 50 条

[1] Adalimumab/etanerceptWorsening of interstitial lung disease: 2 case reports
[J]. Reactions Weekly, 2017, 1668 (1) : 23 - 23
[2] AlectinibFirst report of interstitial lung disease: case report
[J]. Reactions Weekly, 2015, 1541 (1) : 15 - 15
[3] ElotuzumabFirst report of interstitial lung disease: case report
[J]. Reactions Weekly, 2018, 1708 (1) : 141 - 141
[4] AfatinibFatal interstitial lung disease: case report
[J]. Reactions Weekly, 2018, 1712 (1) : 32 - 32
[5] CrizotinibAcute interstitial lung disease: case report
[J]. Reactions Weekly, 2014, 1501 (1) : 16 - 16
[6] Daratumumab Interstitial lung disease: case report
[J]. Reactions Weekly, 2023, 1979 (1) : 145 - 145
[7] OsimertinibAcute interstitial lung disease: case report
[J]. Reactions Weekly, 2016, 1608 (1) : 215 - 215
[8] ErlotinibFatal interstitial lung disease: case report
[J]. Reactions Weekly, 2007, 1176 (1) : 14 - 14
[9] NilotinibIrreversible interstitial lung disease: case report
[J]. Reactions Weekly, 2022, 1899 (1) : 302 - 302
[10] AntineoplasticsFatal interstitial lung disease: case report
[J]. Reactions Weekly, 2011, 1347 (1) : 10 - 10

← 1 2 3 4 5 →